Introduction {#s0001}
============

*ALK* rearrangements resulting in overexpression of the anaplastic lymphoma kinase (*ALK*) protein are the second most common type of genetic aberrations which occurs in non-small-cell lung cancer (NSCLC). These rearrangements are found in \~5% of affected patients.[@cit0001] The gene encoding echinoderm microtubule associated protein like 4 (*EML4*) is a common *ALK* fusion partner, but at least 20 other partners have also been reported.[@cit0002] Patients with *ALK* rearrangements usually benefit from tyrosine-kinase inhibitor (TKI) treatment. However, the inhibitor sensitivity of recombinant *ALK* proteins can vary depending on the nature of the fusion partners.[@cit0003] Furthermore, multiple fusion events can coexist in individual patients,[@cit0004] thereby complicating the tumor response to ALK inhibitors. The development of ALK-specific TKIs has revolutionized the treatment of ALK-rearranged NSCLC. Crizotinib is a first-generation ALK inhibitor that is superior to chemotherapy in terms of tumor control and progression-free survival (PFS).[@cit0005] However, resistance to such inhibitors inevitably develops, with missense mutations encoding amino acid substitutions such as L1196M, C1156Y, G1202R, and I1171N being the most frequent causes of inhibitor failure. The occurrence of these mutations in the *ALK* gene reduces the effectiveness of combined inhibitor and protein therapies, necessitating the development of new treatments. Thus, second-generation inhibitors such as ceritinib, alectinib, and brigatinib, and third-generation inhibitors such as lorlatinib, have now been developed.

Case Description {#s0002}
================

A 53-year-old man presented at our hospital complaining of tightness in the chest. Imaging analyses identified a mass in the right middle lobe of the lung, with ipsilateral thickened pleura and enlarged subcarinal lymph nodes. Lesions in the ipsilateral superior lobe and left eighth rib were considered to be metastatic ([Figure 1A](#f0001){ref-type="fig"}). Thoracentesis confirmed that the medium amount of pleural effusion was hydrothorax with blood. After exfoliative cytology and immunohistochemistry of the hydrothorax (using Ventana ALK D5F3), the patient was diagnosed with ALK-positive lung adenocarcinoma (cT4N2M1, stage IV). Next-generation sequencing (NGS) of genomic DNA isolated from exfoliated adenocarcinoma cells revealed three novel ALK rearrangements: *COX7A2L*--*ALK* (C\[intragenic\]:A20, abundance 41.2%), in which an intron sequence from *COX7A2L* was joined to exon 20 of *ALK; LINC01210--ALK* (L\[intergenic\]:A20, abundance 34.7%), in which an intergenic sequence near to *LINC01210* was joined to exon 20 of *ALK*; and *ATP13A4--ALK* (A9:A19, abundance 21.5%), in which exon 9 of *ATP13A4* was joined to exon 19 of *ALK*. No aberrations were discovered in other common driver genes. The patient's Eastern Cooperative Oncology Group (ECOG) performance status (PS) score was 0. Then patient received crizotinib (250 mg, twice daily) as a first-line treatment. According to the Response Evaluation Criteria in Solid Tumors version 1.1, the patient was evaluated after 2 months of treatment and found to have achieved a partial response (PR), as evidenced by shrinkage of the lung lesions and elimination of lymph-node lesions ([Figure 1B](#f0001){ref-type="fig"}). During crizotinib treatment, the only adverse event was level 1 hypoleukemia, from which the patient recovered following symptomatic treatment. After 12 months PFS, hydrothorax and a subcutaneous node were discovered. Thoracentesis was performed again to obtain exfoliated cancer cells. NGS identified a new rearrangement, *SLCO2A1--ALK* (S\[intergenic\]:A18, abundance 49.9%), and a missense mutation encoding C1156Y. Resistance to crizotinib was also accompanied by an increased abundance of the *COX7A2L--ALK* (53.6%), *LINC01210--ALK* (52.4%) and *ATP13A4--ALK* (33.8%) fusions. Therefore, ceritinib was administered orally once daily (450 mg), on the basis of resistance mutation sensitivity. The results of follow-up computed tomography (CT) scans suggested that the patient experienced 7 months of PFS, with the best evaluation of PR ([Figure 1C](#f0001){ref-type="fig"}). Progression occurred in the lung, and subcutaneous lesions with the recurrence of hydrothorax were observed later. The patient underwent a third thoracentesis for hydrothorax exfoliative cytology and NGS. The *ATP13A4--ALK* and *SLCO2A1--ALK* fusions were no longer detectable. The remaining fusions included *COX7A2L--ALK* (33.8%) and *LINC01210-ALK* (13.3%). The missense mutation C1156Y was also still present.Figure 1Image study and therapeutic evaluation. (**A**) CT scan showed primary lung lesion in right middle lobe and metastasis to subcarinal lymph node, ipsilateral lung and left eighth rib in baseline; (**B**) PR assessment during crizotinib because of the shrinking of lung lesions and elimination of lymph node; (**C**) progression when resistant to crizotinib (hydrothorax and subcutaneous metastasis) and the partial response (PR) to ceritinib in hydrothorax elimination and subcutaneous lesion control.

Discussion {#s0003}
==========

We have presented here the first known case of a NSCLC patient in whom four *ALK* gene fusions coexisted. These rearrangements were *COX7A2L--ALK* (C\[intragenic\]:A20), *LINC01210--ALK* (L\[intergenic\]:A20), *ATP13A4--ALK* (A9:A19) and *SLCO2A1--ALK* (S\[intergenic\]:A18). To the best of our knowledge, these events are rare and constitute the first report. The abundance of each rearrangement changed over the course of treatment with targeted therapies ([Table 1](#t0001){ref-type="table"}). At baseline, we detected three fusions (*COX7A2L--ALK, LINC01210--ALK* and *ATP13A4--ALK*), and the patient received crizotinib. NGS at progression additionally detected an *SLCO2A1--ALK* fusion. The patient then received second-line ceritinib until progression, at which point *ATP13A4--ALK* and *SLCO2A1--ALK* were no longer detected, indicating that resistance had developed again.Table 1Abundance of *ALK* Mutations at Different Stages of the Patient's TreatmentStage*COX7A2L--ALKLINC01210--ALKATP13A4--ALKSLCO2A1--ALK*C1156YBaseline41.2%34.7%21.5%N.D.N.D.Crizotinib-resistant53.6%52.4%33.8%49.9%27.1%Ceritinib-resistant33.8%13.3%N.D.N.D.25.8%[^1]

Among the four rearrangement partners, *ATP13A4*, which is located on chromosome 3, was the only gene to contribute exon sequences. The protein encoded by *ATP13A4* gene is a member of the subfamily of P5-type ATPases, and is involved in cardiac conduction and the transport of glucose and other sugars, bile salts, organic acids, metal ions and amine compounds.[@cit0006] By contrast, intergenic and intragenic *ALK* fusions are rare mutations in which the rearrangement partners do not contribute exon sequences to the gene fusions. Intergenic fragments are gene spacer sequences that are located near to the partner gene, whereas intragenic fragments are derived from intron regions of the partner gene. It is unknown whether these intergenic and intragenic fusions are tumor drivers. Further analysis of the fragment functions and mRNA sequences may provide additional information.

The development of ALK inhibitors has resulted in considerable improvements in survival among patients diagnosed with NSCLC with *ALK*-rearrangement. However, these patients inevitably acquire treatment resistance. Along with missense mutations, the acquisition and loss of *ALK* rearrangements may also be involved in inhibitor resistance. In this case, an *SLCO2A1--ALK* (S\[intergenic\]:A18) fusion was detected by NGS following the development of resistance to crizotinib. Some evidence suggests that rare fusions may contribute to crizotinib resistance.[@cit0007] The development of rearrangements encoding TKI-insensitive ALK might, therefore, lead to acquired resistance. Notably, resistance to epidermal growth factor receptor (EGFR) TKIs has been observed in patients with NSCLC and *EGFR* mutations who acquired *EML4--ALK* fusions.[@cit0008] Loss of *ALK* rearrangements can also lead to resistance.[@cit0009] Additionally, no new missense mutations were detected when the patient was assessed for progression following ceritinib treatment. In this regard, we believed the disappearance of the *ATP13A4--ALK* and *SLCO2A1--ALK* rearrangements is in association with the development of resistance to ceritinib. The maintenance of the crizotinib-resistant C1156Y mutation indicated that retained *COX7A2L--ALK* and *LINC01210--ALK* might have been involved in tumor growth and sensitivity to crizotinib.

Conclusion {#s0004}
==========

*ATP13A4--ALK* is a therapeutic target for ALK-rearrangement NSCLC. Intergenic and intragenic *ALK* fusions might be involved in tumor growth and sensitivity to ALK TKIs. Both acquisition and loss of *ALK* fusions after inhibitor treatment might lead to resistance.

Abbreviations {#s0005}
=============

NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor; NGS, next-generation sequencing; ALK, anaplastic lymphoma kinase; EML4, echinoderm microtubule associated protein like 4; PFS, progression-free survival; ECOG, Eastern Cooperative Oncology Group; PS, performance status; PR, partial response; CT, computed tomography; N.D., not detected; EGFR, epidermal growth factor receptor.
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